

Primary treatment of prostate cancer: Balancing benefits and side effects

Poster Session 81

Monday, 27 March
15:45 - 17:15

Location: Room Milan, North Hall (Level 1)

Chairs: G.M. Ahlgren, Malmö (SE)
G. Giannarini, Udine (IT)
R.C.N. Van Den Bergh, Amsterdam (NL)

Aims and objectives of this session

The aim of this session is to discuss on oncological and functional outcomes on primary treatments for prostate cancer.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 1070 **The BAUS radical prostatectomy audit 2014/2015 – an update on current practice and outcomes by centre and surgeon case volume**
By: [Khadhoury S.](#)¹, Miller C.¹, McNeill A.², Hounsoms L.³, Fowler S.⁴, McGrath J.¹
Institutes:¹Royal Devon and Exeter Hospital, Dept. of Urology, Exeter, United Kingdom, ²Western General Hospital, Dept. of Urology, Edinburgh, United Kingdom, ³Public Health England, Dept. of Public Health, London, United Kingdom, ⁴BAUS, Dept. of Surgery, London, United Kingdom
- 1071 **Efficacy of local treatment in prostate cancer patients with clinically pelvic lymph node-positive disease at initial diagnosis**
By: [Seisen T.](#)¹, Vetterlein M.¹, Karabon P.¹, Jindal T.¹, Sood A.¹, Nocera L.¹, Nguyen P.², Choueiri T.³, Trinh Q-D.⁴, Menon M.¹, Abdollah F.¹
Institutes:¹Henri Ford Hospital, Dept. of Urology, Detroit, United States of America, ²Brigham and Women Hospital, Dept. of Radiation Oncology, Boston, United States of America, ³Dana Farber Cancer Institute, Dept. of Genito-Urinary Medical Oncology, Boston, United States of America, ⁴Brigham and Women's Hospital, Dept. of Urology, Boston, United States of America
- 1072 **Oncological and functional outcomes of laparoscopic versus robot-assisted radical prostatectomy: Five years results of a prospective randomised controlled trial**
By: Porpiglia F.¹, [Fiori C.](#)¹, Bertolo R.¹, Manfredi M.¹, Mele F.¹, Garrou D.¹, Cattaneo G.¹, De Luca S.¹, Passera R.², Scarpa R.M.¹
Institutes:¹San Luigi Hospital, Dept. of Urology, Turin, Italy, ²San Giovanni Battista Hospital, Dept. of Nuclear Medicine, Turin, Italy
- 1073 **Contemporary extended pelvic lymph node dissection for prostate cancer in the UK – an analysis of national practice**
By: Calleja E., Fowler S., McGrath J., Sooriakumaran P., [Aning J.](#)
Institutes:BAUS Section of Oncology, British Association of Urological Surgeons, London, United Kingdom
- 1075 **More extensive lymph node dissection at radical prostatectomy is associated with improved outcomes after salvage radiotherapy for rising PSA after surgery: A long-term, multi-institutional analysis**
By: [Fossati N.](#)¹, Karnes R.J.², Colicchia M.², Bossi A.³, Cozzarini C.⁴, Fiorino C.⁴, Noris Chiorda B.⁴, Gandaglia G.¹, Dell'Oglio P.¹, Wiegel T.⁵, Shariat S.⁶, Goldner G.⁷, Joniau S.⁸, Battaglia A.⁸, Haustermans K.⁹, De Meerleer G.⁹, Fonteyne V.¹⁰, Ost P.¹⁰, Van Poppel H.⁵, Montorsi F.¹, Briganti A.¹, Boorjian S.A.²
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Mayo Clinic, Dept. of Urology, Rochester, United States of America, ³Gustave Roussy Institute, Dept. of Radiation

Oncology, Villejuif, France, ⁴IRCCS Ospedale San Raffaele, Dept. of Radiotherapy, Milan, Italy, ⁵ University Hospital Ulm, Dept. of Radiation Oncology, Ulm, Germany, ⁶Medical University of Vienna, Dept. of Urology, Vienna, Austria, ⁷Medical University of Vienna, Dept. of Radiation Oncology, Vienna, Austria, ⁸University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁹University Hospitals Leuven, Dept. of Radiotherapy, Leuven, Belgium, ¹⁰Ghent University Hospital, Dept. of Radiotherapy, Ghent, Belgium

- 1074 **Applicability of Briganti nomogram: Is it an absolute requirement before lymph node dissection in intermediate-risk prostate cancer? Assessment of the external applicability**
By: Pradere B., Roumiguié M., Sanson S., Gas J., Patard P.M., Huyghe E., Rischmann P., Gamé X., Thoulouzan M., Doumerc N., Soulié M., Beauval J.B.
Institutes: CHU Toulouse, Dept. of Urology, Toulouse, France
- 1076 **The CPC risk calculator app: A validated tool to predict recurrence after radical prostatectomy.**
By: Røder M.A.¹, Berg K.D.¹, Loft M.D.², Gerds T.A.³, Ferrari M.², Thomsen F.B.¹, Gruschy L.¹, Kurbegovic S.¹, Rytgaard H.C.³, Kjær A.⁴, Brasso K.¹, Iversen P.¹, Brooks J.²
Institutes: ¹Rigshospitalet, Copenhagen Prostate Cancer Center, Dept. of Urology, Copenhagen, Denmark, ²Stanford University Medical Center, Dept. of Urology, Stanford, United States of America, ³University of Copenhagen, Dept. of Biostatistics, Copenhagen, Denmark, ⁴Rigshospitalet, Dept. of Clinical Physiology, Nuclear Medicine & PET and Cluster For Molecular Imaging, Copenhagen, Denmark
- 1077 **Obesity was associated with improved metastases-free survival after surgery in 13,667 prostate cancer patients**
By: Tennstedt P.¹, Salomon G.¹, Tilki D.¹, Budäus L.¹, Pompe R.¹, Leyh-Bannurah S-R.², Haese A.¹, Heinzer H.¹, Huland H.¹, Graefen M.¹, Schifmann J.³
Institutes: ¹University Medical Center Eppendorf, Martini-Klinik, Hamburg, Germany, ²University Medical Center Eppendorf, Department of Urology, Hamburg, Germany, ³Academic Hospital Braunschweig, Department of Urology, Braunschweig, Germany
- 1078 **Functional outcomes and complications of a multicentre series of open versus robot-assisted salvage radical prostatectomy**
By: Gontero P.¹, Marra G.¹, Alessio P.¹, Oderda M.¹, Palazzetti A.¹, Pisano F.¹, Battaglia A.¹, Munegato S.¹, Frea B.¹, Munoz F.², Filippini C.³, Linares E.⁴, Sanchez-Salas R.⁴, Goonewardene S.⁵, Dasgupta P.⁵, Cahill D.⁵, Challacombe B.⁵, Popert R.⁵, Gillatt D.⁶, Persad R.⁶, Palou J.⁷, Joniau S.⁸, Smelzo S.⁹, Piechaud T.⁹, De La Taille A.¹⁰, Roupert M.¹¹, Albisinni S.¹², Van Velthoven R.¹², Morlacco A.¹³, Vidit S.¹³, Gandaglia G.¹⁴, Mottrie A.¹⁴, Smith J.¹⁵, Fiscus G.¹⁵, Van Der Poel H.¹⁶, Tilki D.¹⁷, Karnes R.J.¹³
Institutes: ¹San Giovanni Battista Hospital, Dept. of Urology, Turin, Italy, ²Pasini Hospital, Dept. of Radiotherapy, Aosta, Italy, ³San Giovanni Battista Hospital, Dept. of Statistics, Turin, Italy, ⁴Institut Mutualiste Montsouris, Dept. of Urology, Paris, France, ⁵Guy's Hospital, Dept. of Urology, London, United Kingdom, ⁶North Bristol NHS Foundation Trust, Dept. of Urology, Bristol, United Kingdom, ⁷Fundació Puigvert, Dept. of Urology, Barcelona, Spain, ⁸Leuven University Hospitals, Dept. of Urology, Leuven, Belgium, ⁹Clinique Saint Augustin, Dept. of Urology, Bordeaux, France, ¹⁰CHU Mondor, Dept. of Urology, Créteil, France, ¹¹Pitié Salpêtrière Hospital- University Paris 6, Dept. of Urology, Paris, France, ¹²Institut Jules Bordet, Université Libre De Bruxelles, Dept. of Urology, Brussels, Belgium, ¹³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ¹⁴OLV Hospital, Dept. of Urology, Aalst, Belgium, ¹⁵Vanderbilt University, Medical Center North, Dept. of Urology, Nashville, United States of America, ¹⁶Netherlands Cancer Institute, Dept. of Urology, Amsterdam, The Netherlands, ¹⁷Martini Klinik, Dept. of Urology, Hamburg, Germany
- 1079 **Impact of type of radical prostatectomy on outcomes reported by men with prostate cancer 18 months post-diagnosis: Results from the English National Prostate Cancer Audit (NPCA)**
By: Nossiter J.¹, Sujenthiran A.², Charman S.³, Cathcart P.⁴, Aggarwal A.³, Payne H.⁵, Clarke N.⁶, Van Der Meulen J.⁷
Institutes: ¹Royal College Of Surgeons Of England, Dept. of Clinical Effectiveness, London, United Kingdom, ²Royal College Of Surgeons Of England, Dept. of Clinical Effectiveness, London, United Kingdom, ³London School of Hygiene and Tropical Medicine, Dept. of Health Services Research & Policy, London, United Kingdom, ⁴Guy's and St Thomas' Hospital, NHS Foundation Trust, London,

United Kingdom, ⁵University College London Hospitals, London NHS Foundation Trust, London, United Kingdom, ⁶The Christie and Salford Royal NHS Foundation Trusts, NHS Foundation Trusts, London, United Kingdom, ⁷ London School of Hygiene and Tropical Medicine, Dept. of Health Services Research & Policy, London, United Kingdom

- 1081 **Randomized study evaluating postoperative outcomes in patients with complex anastomosis during da Vinci prostatectomy**
By: Pushkar D., Kolontarev K., Govorov A., Rasner P.
Institutes: Moscow State Medico Stomatological University, Hospital 50, Dept. of Urology, Moscow, Russia
- 1082 **Surgical expertise is the major determinant of decreased complication rates in contemporary patients treated with robot-assisted radical prostatectomy**
By: Dell'Oglio P.¹, Stabile A.¹, Zaffuto E.¹, Gandaglia G.¹, Fossati N.¹, Bandini M.¹, Moschini M.¹, Fallara G.¹, Dehò F.¹, Guazzoni G.², Gallina A.¹, Suardi N.¹, Gaboardi F.¹, Montorsi F.¹, Briganti A.¹
Institutes:¹Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ²Humanitas Clinical and Research Center, Dept. of Urology, Milan, Italy
- 1083 **Characterization of the "one-pad patient" at long-term follow-up after radical prostatectomy**
By: Löppenber B., Müller G., Bach P., Von Bodman C., Brock M., Roghmann F., Noldus J., Palisaar J.
Institutes: Ruhr-University Bochum, Marien Hospital Herne, Dept. of Urology, Herne, Germany